FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
- Sale of FibroGen China to AstraZeneca increased by $25M to $185M total consideration
- Cash runway extended into 2H 2027 after China sale closure
- Net loss improved from $49.0M in Q1 2024 to $16.8M in Q1 2025
- Maintains roxadustat rights in U.S. and markets outside China, South Korea, and Astellas-licensed territories
- Revenue declined significantly from $25.4M in Q1 2024 to $2.7M in Q1 2025
- Current cash position relatively low at $33.8M in U.S. operations
Insights
FibroGen's improved China sale terms and extended cash runway strengthen financial position while advancing promising oncology pipeline.
FibroGen's Q1 2025 results reveal significant strategic developments that strengthen the company's financial outlook. The $25 million increase in the total consideration for the FibroGen China sale to AstraZeneca - now at
The most critical financial impact is the extended cash runway into 2H 2027 following the sale's anticipated Q3 2025 closing. This runway extension provides FibroGen with crucial operational flexibility to execute its clinical development strategy without immediate financing pressures. The company reported
From a pipeline perspective, FibroGen's focus on advancing FG-3246, its CD46-targeting antibody-drug conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC), represents a strategic pivot toward high-value oncology assets. The publication of Phase 1 results in the Journal of Clinical Oncology adds scientific credibility to this program. The upcoming Phase 2 monotherapy dose optimization study in Q3 2025 and expected topline combination therapy results in Q4 2025 are critical value-inflection points.
FibroGen's Type-C meeting request with the FDA regarding roxadustat for lower-risk myelodysplastic syndromes (LR-MDS) demonstrates continued commitment to expanding its treatment portfolio. The net loss from continuing operations of
FibroGen secures better AstraZeneca deal terms and significantly extends cash runway while advancing key clinical programs.
The revised terms of the FibroGen China transaction represent a material financial improvement for the company. The
FibroGen's cash runway extension into 2H 2027 following the expected Q3 2025 transaction close is particularly significant. This extended operational timeline dramatically reduces near-term financing risk, providing approximately 2+ years of additional runway. The transaction structure -
The company's financial position shows
The planned debt repayment to Morgan Stanley Tactical Value following the China transaction close will simplify FibroGen's capital structure, reducing interest expenses and removing restrictive covenants. This financial restructuring, combined with the extended cash runway, provides FibroGen with sufficient capital to reach multiple clinical milestones for FG-3246 and potentially advance roxadustat in LR-MDS, both of which represent significant potential value catalysts.
From an investment perspective, FibroGen's pipeline advancement timelines are now fully funded through key inflection points. The Phase 2 monotherapy optimization study and combination therapy data readouts expected in late 2025 will be critical for assessing FG-3246's commercial potential in the lucrative prostate cancer market, while maintaining optionality around roxadustat's development in additional indications.
- Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately
$185 million , a$25 million increase from initial guidance- Net cash held in China at closing now estimated to be approximately
$100 million - Transaction expected to close in 3Q 2025
- Net cash held in China at closing now estimated to be approximately
- Upon close of sale of FibroGen China, cash runway extended into 2H 2027
- Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025
- Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 4Q 2025
- Filed Type-C meeting request with FDA for roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS)
- Expect feedback on potential path forward in 3Q 2025
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2025 and provided an update on the company’s recent developments.
“We continue to focus on our most important strategic priority of advancing our lead asset, FG-3246, with the initiation of the Phase 2 monotherapy dose optimization study in mCRPC, expected to start in the third quarter of 2025,” said Thane Wettig, Chief Executive Officer, FibroGen. “In addition, we have filed a Type C meeting request with the FDA to discuss the potential Phase 3 development program for roxadustat in the treatment of anemia associated with LR-MDS, an indication with significant unmet medical need. As we look to finalize the sale of FibroGen China in the third quarter of 2025, we remain highly focused on driving significant shareholder value by supporting our US development initiatives with our strong balance sheet and extended cash runway into the second half of 2027.”
Recent Developments and Key Highlights of First Quarter 2025:
- Sale of FibroGen China to AstraZeneca now expected to be for a total consideration of approximately
$185 million , representing an enterprise value of$85 million plus estimated net cash held in China at closing of approximately$100 million . The transaction is expected to close in the third quarter of 2025.- Upon closing, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structure.
- FibroGen maintains its rights to roxadustat in the U.S. and in all markets outside of China, South Korea, and those licensed to Astellas.
- Publication of results from Phase 1 Monotherapy Study of FG-3246 titled, “A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients with Metastatic Castration Resistant Prostate Cancer", in the peer-reviewed Journal of Clinical Oncology (JCO). The trial results provide key insights into the clinical impact of targeting CD46 and its potential to become the next generation target in the prostate cancer treatment paradigm.
Upcoming Milestones:
FG-3246 (CD46 Targeting ADC) and FG-3180 (CD46 Targeting PET Imaging Agent)
- Anticipate initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC in the third quarter of 2025.
- Phase 2 trial will include FG-3180 to enable assessment of its diagnostic performance and the potential correlation between CD46 expression and response to FG-3246.
- Topline results from the Phase 2 portion of the investigator-sponsored Phase 1b/2 study conducted by UCSF of FG-3246 in combination with enzalutamide in patients with mCRPC expected in the fourth quarter of 2025.
- Phase 2 portion of the study will include data on FG-3180.
Roxadustat
- Filed a Type-C meeting request with the FDA for roxadustat in anemia associated with LR-MDS. The Company expects feedback on a potential path forward in the third quarter of 2025.
Financial:
- Total revenue from continuing operations for the first quarter of 2025 was
$2.7 million , as compared to$25.4 million for the first quarter of 2024. - Net loss from continuing operations for the first quarter of 2025 was
$16.8 million , or$0.16 net loss per basic and diluted share, compared to a net loss of$49.0 million , or$0.49 net loss per basic and diluted share, one year ago. - At March 31, 2025, FibroGen reported
$33.8 million in cash, cash equivalents and accounts receivable in the U.S. and$128.4 million in total consolidated cash, cash equivalents and accounts receivable. - Upon closing of the announced sale of FibroGen China, the Company expects its cash, cash equivalents and accounts receivable to be sufficient to fund our operating plans into the second half of 2027.
Conference Call and Webcast Presentation
The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on FibroGen’s website.
About FG-3246
FG-3246 (FOR46) is a potential first-in-class fully human antibody-drug conjugate (ADC), exclusively in-licensed from Fortis Therapeutics, and is being developed by FibroGen for metastatic castration-resistant prostate cancer and potentially other tumor types. FG-3246 binds to an epitope of CD46, a cell receptor target, that induces internalization upon antibody binding, is present at high levels in prostate cancer and other tumor types and demonstrates very limited expression in most normal tissues. FG-3246 is comprised of an anti-CD46 antibody, YS5, linked to the anti-mitotic agent, MMAE, which is a clinically and commercially validated ADC payload. FG-3246 has demonstrated anti-tumor activity in both preclinical and clinical studies.
FG-3246 is currently in an ongoing Phase 1b/2 study being conducted at UCSF as an investigator-sponsored trial to evaluate FG-3246 in combination with enzalutamide. An additional investigator-sponsored radiopharmaceutical marker trial using a zirconium-89 positron emission tomography (PET) tracer for CD46 that utilizes the YS5 antibody is also underway at UCSF. The initiation of the Phase 2 monotherapy dose optimization trial for FG-3246 in metastatic castration-resistant prostate cancer is anticipated in the third quarter of 2025. FG-3246 is an investigational drug and not approved for marketing by any regulatory authority.
About Roxadustat
Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted by the China Health Authority.
Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). FibroGen has the sole rights to roxadustat in the United States, Canada, Mexico, and in all markets not held by AstraZeneca or licensed to Astellas. Astellas and FibroGen are collaborating on the commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, Turkey, Russia, and the Commonwealth of Independent States, the Middle East, and South Africa.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com.
Forward-Looking Statements
This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of FibroGen products and product candidates, statements under the caption “Upcoming Milestones”, statements about regulatory interactions, the net cash portion of the purchase price and closing of the sale of FibroGen China as well as the payoff of the Morgan Stanley Tactical Value term loan, statements regarding cash, such as the expectation that cash, cash equivalents and accounts receivable will be sufficient to fund FibroGen’s operating plans into the second half of 2027, and statements about FibroGen’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.
| Condensed Consolidated Balance Sheets (In thousands) | |||||||
| March 31, 2025 | December 31, 2024 | ||||||
| (Unaudited) | (1) | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 33,609 | $ | 50,482 | |||
| Accounts receivable, net | 147 | 481 | |||||
| Inventory | 3,155 | 3,155 | |||||
| Prepaid expenses and other current assets | 3,326 | 31,542 | |||||
| Current assets held for sale | 108,292 | 110,849 | |||||
| Total current assets | 148,529 | 196,509 | |||||
| Other assets | 1,121 | 1,405 | |||||
| Long-term assets held for sale | 15,563 | 16,611 | |||||
| Total assets | $ | 165,213 | $ | 214,525 | |||
| Liabilities, stockholders’ equity and non-controlling interests | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 7,282 | $ | 5,064 | |||
| Accrued and other liabilities | 35,324 | 62,035 | |||||
| Deferred revenue | 22,509 | 27,290 | |||||
| Current liabilities held for sale | 8,275 | 38,917 | |||||
| Total current liabilities | 73,390 | 133,306 | |||||
| Product development obligations | 17,799 | 17,012 | |||||
| Deferred revenue, net of current | 115,347 | 114,708 | |||||
| Senior secured term loan facilities, non-current | 73,419 | 73,092 | |||||
| Liability related to sale of future revenues, non-current | 59,168 | 58,864 | |||||
| Other long-term liabilities | 830 | 822 | |||||
| Long-term liabilities held for sale | 189 | 356 | |||||
| Total liabilities | 340,142 | 398,160 | |||||
| Redeemable non-controlling interests | 21,480 | 21,480 | |||||
| Total stockholders’ deficit attributable to FibroGen | (216,896 | ) | (225,602 | ) | |||
| Nonredeemable non-controlling interests | 20,487 | 20,487 | |||||
| Total deficit | (196,409 | ) | (205,115 | ) | |||
| Total liabilities, redeemable non-controlling interests and deficit | $ | 165,213 | $ | 214,525 | |||
(1) The condensed consolidated balance sheet amounts at December 31, 2024 are derived from audited financial statements.
| Condensed Consolidated Statements of Operations (In thousands, except per share data) | |||||||
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| (Unaudited) | |||||||
| Revenue: | |||||||
| Development and other revenue | $ | 144 | $ | 878 | |||
| Drug product revenue, net | 2,595 | 24,486 | |||||
| Total revenue | 2,739 | 25,364 | |||||
| Operating costs and expenses: | |||||||
| Cost of goods sold | 252 | 21,343 | |||||
| Research and development | 9,175 | 36,489 | |||||
| Selling, general and administrative | 8,106 | 16,714 | |||||
| Restructuring charge | 126 | — | |||||
| Total operating costs and expenses | 17,659 | 74,546 | |||||
| Loss from operations | (14,920 | ) | (49,182 | ) | |||
| Interest and other, net: | |||||||
| Interest expense | (2,257 | ) | (2,092 | ) | |||
| Interest income and other income (expenses), net | 413 | 2,235 | |||||
| Total interest and other, net | (1,844 | ) | 143 | ||||
| Loss from continuing operations before income taxes | (16,764 | ) | (49,039 | ) | |||
| Provision for income taxes | 2 | 7 | |||||
| Loss from continuing operations | (16,766 | ) | (49,046 | ) | |||
| Income from discontinued operations, net of tax | 21,405 | 16,113 | |||||
| Net income (loss) | $ | 4,639 | $ | (32,933 | ) | ||
| Loss from continuing operations per share - basic and diluted | $ | (0.16 | ) | $ | (0.49 | ) | |
| Income from discontinued operations per share - basic and diluted | 0.21 | 0.16 | |||||
| Net income (loss) per share - basic and diluted | $ | 0.05 | $ | (0.33 | ) | ||
| Weighted average number of common shares used to calculate net income (loss) per share - basic and diluted | 100,954 | 98,982 | |||||
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com
FAQ
What is the total value of FibroGen's China sale to AstraZeneca in 2025?
What was FGEN's revenue and net loss in Q1 2025?
When will FibroGen's Phase 2 trial for FG-3246 in prostate cancer begin?
How long will FibroGen's cash runway extend after the China sale?
What is FibroGen's current cash position as of March 2025?
